Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Immunotherapy in Combination with Radiation Therapy, with or without Platinum Doublet Chemotherapy, for the Treatment of Patients with Stage II or III Locally Advanced and Unresectable Non-Small Cell Lung Cancer, TRIPL Trial

Trial Status: active

This phase II trial tests how well immunotherapy (cemiplimab and fianlimab) in combination with radiation therapy, with or without platinum doublet chemotherapy, works in treating patients with stage II or III non-small cell lung cancer (NSCLC) that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as cemiplimab and fianlimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Platinum doublet chemotherapy is a drug combination of platinum compounds, which work by killing, stopping or slowing the growth of tumor cells. Combining immunotherapy with radiation therapy, with or without platinum doublet chemotherapy, may be effective at treating patients with stage II or III locally advanced and unresectable on-small cell lung cancer.